ERBB2 and breast carcinoma: Regarding breast cancer subtypes, within Groups 1-4, patients with HER2-positive or Triple-Positive tumors demonstrated improved survival compared to those with Hormone- receptor positive tumors (HR 0.86, 95% CI 0.79-0.94, p=0.001; and HR 0.73, 95% CI 0.67-0.81, p<0.0001, respectively).